Iopentol (Imagopaque 300) compared with ioxaglate (Hexabrix 320) in knee arthrography. A clinical trial assessing immediate and late adverse events and diagnostic information.

Abstract

This trial was designed to compare the incidence of delayed postprocedural pain after administration of iopentol (Imagopaque, Nycomed Imaging AS, Oslo, Norway) 300 mg I/ml versus ioxaglate (Hexabrix, Guerbet, Aulnay-sous-Bois, France) 320 mg I/ml in single-contrast knee arthrography. Other adverse events and radiographic efficacy were also evaluated.